355 related articles for article (PubMed ID: 29763623)
1. Molecular, Pathological, Radiological, and Immune Profiling of Non-brainstem Pediatric High-Grade Glioma from the HERBY Phase II Randomized Trial.
Mackay A; Burford A; Molinari V; Jones DTW; Izquierdo E; Brouwer-Visser J; Giangaspero F; Haberler C; Pietsch T; Jacques TS; Figarella-Branger D; Rodriguez D; Morgan PS; Raman P; Waanders AJ; Resnick AC; Massimino M; Garrè ML; Smith H; Capper D; Pfister SM; Würdinger T; Tam R; Garcia J; Thakur MD; Vassal G; Grill J; Jaspan T; Varlet P; Jones C
Cancer Cell; 2018 May; 33(5):829-842.e5. PubMed ID: 29763623
[TBL] [Abstract][Full Text] [Related]
2. Radiological Evaluation of Newly Diagnosed Non-Brainstem Pediatric High-Grade Glioma in the HERBY Phase II Trial.
Rodriguez Gutierrez D; Jones C; Varlet P; Mackay A; Warren D; Warmuth-Metz M; Aliaga ES; Calmon R; Hargrave DR; Cañete A; Massimino M; Azizi AA; Le Deley MC; Saran F; Rousseau RF; Zahlmann G; Garcia J; Vassal G; Grill J; Morgan PS; Jaspan T
Clin Cancer Res; 2020 Apr; 26(8):1856-1865. PubMed ID: 31924736
[TBL] [Abstract][Full Text] [Related]
3. WHO grade has no prognostic value in the pediatric high-grade glioma included in the HERBY trial.
Varlet P; Le Teuff G; Le Deley MC; Giangaspero F; Haberler C; Jacques TS; Figarella-Branger D; Pietsch T; Andreiuolo F; Deroulers C; Jaspan T; Jones C; Grill J
Neuro Oncol; 2020 Jan; 22(1):116-127. PubMed ID: 31419298
[TBL] [Abstract][Full Text] [Related]
4. Phase II, Open-Label, Randomized, Multicenter Trial (HERBY) of Bevacizumab in Pediatric Patients With Newly Diagnosed High-Grade Glioma.
Grill J; Massimino M; Bouffet E; Azizi AA; McCowage G; Cañete A; Saran F; Le Deley MC; Varlet P; Morgan PS; Jaspan T; Jones C; Giangaspero F; Smith H; Garcia J; Elze MC; Rousseau RF; Abrey L; Hargrave D; Vassal G
J Clin Oncol; 2018 Apr; 36(10):951-958. PubMed ID: 29412784
[TBL] [Abstract][Full Text] [Related]
5. A long-term survivor of pediatric midline glioma with H3F3A K27M and BRAF V600E double mutations.
Nakano Y; Yamasaki K; Sakamoto H; Matsusaka Y; Kunihiro N; Fukushima H; Inoue T; Honda-Kitahara M; Hara J; Yoshida A; Ichimura K
Brain Tumor Pathol; 2019 Oct; 36(4):162-168. PubMed ID: 31254135
[TBL] [Abstract][Full Text] [Related]
6. Co-occurrence of histone H3 K27M and BRAF V600E mutations in paediatric midline grade I ganglioglioma.
Pagès M; Beccaria K; Boddaert N; Saffroy R; Besnard A; Castel D; Fina F; Barets D; Barret E; Lacroix L; Bielle F; Andreiuolo F; Tauziède-Espariat A; Figarella-Branger D; Puget S; Grill J; Chrétien F; Varlet P
Brain Pathol; 2018 Jan; 28(1):103-111. PubMed ID: 27984673
[TBL] [Abstract][Full Text] [Related]
7. Recurrent copy number alterations in low-grade and anaplastic pleomorphic xanthoastrocytoma with and without BRAF V600E mutation.
Vaubel RA; Caron AA; Yamada S; Decker PA; Eckel Passow JE; Rodriguez FJ; Nageswara Rao AA; Lachance D; Parney I; Jenkins R; Giannini C
Brain Pathol; 2018 Mar; 28(2):172-182. PubMed ID: 28181325
[TBL] [Abstract][Full Text] [Related]
8. Bevacizumab, irinotecan, temozolomide, tyrosine kinase inhibition, and MEK inhibition are effective against pleomorphic xanthoastrocytoma regardless of V600E status.
Thompson EM; Landi D; Ashley D; Keir ST; Bigner D
J Neurooncol; 2018 Nov; 140(2):261-268. PubMed ID: 30120661
[TBL] [Abstract][Full Text] [Related]
9. A pilot study of bevacizumab-based therapy in patients with newly diagnosed high-grade gliomas and diffuse intrinsic pontine gliomas.
Hummel TR; Salloum R; Drissi R; Kumar S; Sobo M; Goldman S; Pai A; Leach J; Lane A; Pruitt D; Sutton M; Chow LM; Grimme L; Doughman R; Backus L; Miles L; Stevenson C; Fouladi M; DeWire M
J Neurooncol; 2016 Mar; 127(1):53-61. PubMed ID: 26626490
[TBL] [Abstract][Full Text] [Related]
10. The molecular characteristics of spinal cord gliomas with or without H3 K27M mutation.
Chai RC; Zhang YW; Liu YQ; Chang YZ; Pang B; Jiang T; Jia WQ; Wang YZ
Acta Neuropathol Commun; 2020 Mar; 8(1):40. PubMed ID: 32228694
[TBL] [Abstract][Full Text] [Related]
11. Genetic signature and treatment of pediatric high-grade glioma.
Guidi M; Giunti L; Buccoliero AM; Caporalini C; Censullo ML; Galli L; Genitori L; Sardi I
Mol Clin Oncol; 2021 Apr; 14(4):70. PubMed ID: 33732456
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the Implementation of the Response Assessment in Neuro-Oncology Criteria in the HERBY Trial of Pediatric Patients with Newly Diagnosed High-Grade Gliomas.
Rodriguez D; Chambers T; Warmuth-Metz M; Aliaga ES; Warren D; Calmon R; Hargrave D; Garcia J; Vassal G; Grill J; Zahlmann G; Morgan PS; Jaspan T
AJNR Am J Neuroradiol; 2019 Mar; 40(3):568-575. PubMed ID: 30819765
[TBL] [Abstract][Full Text] [Related]
13. Targeting Epigenetic Pathways in the Treatment of Pediatric Diffuse (High Grade) Gliomas.
Vanan MI; Underhill DA; Eisenstat DD
Neurotherapeutics; 2017 Apr; 14(2):274-283. PubMed ID: 28233220
[TBL] [Abstract][Full Text] [Related]
14. Randomized prospective trial of fractionated stereotactic radiosurgery with chemotherapy versus chemotherapy alone for bevacizumab-resistant high-grade glioma.
Bergman D; Modh A; Schultz L; Snyder J; Mikkelsen T; Shah M; Ryu S; Siddiqui MS; Walbert T
J Neurooncol; 2020 Jun; 148(2):353-361. PubMed ID: 32444980
[TBL] [Abstract][Full Text] [Related]
15. Vorinostat, temozolomide or bevacizumab with irradiation and maintenance BEV/TMZ in pediatric high-grade glioma: A Children's Oncology Group Study.
Lulla RR; Buxton A; Krailo MD; Lazow MA; Boue DR; Leach JL; Lin T; Geller JI; Kumar SS; Nikiforova MN; Chandran U; Jogal SS; Nelson MD; Onar-Thomas A; Haas-Kogan DA; Cohen KJ; Kieran MW; Gajjar A; Drissi R; Pollack IF; Fouladi M
Neurooncol Adv; 2024; 6(1):vdae035. PubMed ID: 38596718
[TBL] [Abstract][Full Text] [Related]
16. BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implications.
Dias-Santagata D; Lam Q; Vernovsky K; Vena N; Lennerz JK; Borger DR; Batchelor TT; Ligon KL; Iafrate AJ; Ligon AH; Louis DN; Santagata S
PLoS One; 2011 Mar; 6(3):e17948. PubMed ID: 21479234
[TBL] [Abstract][Full Text] [Related]
17. A clinicopathologic study of diencephalic pediatric low-grade gliomas with BRAF V600 mutation.
Ho CY; Mobley BC; Gordish-Dressman H; VandenBussche CJ; Mason GE; Bornhorst M; Esbenshade AJ; Tehrani M; Orr BA; LaFrance DR; Devaney JM; Meltzer BW; Hofherr SE; Burger PC; Packer RJ; Rodriguez FJ
Acta Neuropathol; 2015 Oct; 130(4):575-85. PubMed ID: 26264609
[TBL] [Abstract][Full Text] [Related]
18. Children with DIPG and high-grade glioma treated with temozolomide, irinotecan, and bevacizumab: the Seattle Children's Hospital experience.
Crotty EE; Leary SES; Geyer JR; Olson JM; Millard NE; Sato AA; Ermoian RP; Cole BL; Lockwood CM; Paulson VA; Browd SR; Ellenbogen RG; Hauptman JS; Lee A; Ojemann JG; Vitanza NA
J Neurooncol; 2020 Jul; 148(3):607-617. PubMed ID: 32556862
[TBL] [Abstract][Full Text] [Related]
19. Concurrent radiotherapy with temozolomide vs. concurrent radiotherapy with a cisplatinum-based polychemotherapy regimen : Acute toxicity in pediatric high-grade glioma patients.
Seidel C; von Bueren AO; Bojko S; Hoffmann M; Pietsch T; Gielen GH; Warmuth-Metz M; Bison B; Kortmann RD; Kramm CM
Strahlenther Onkol; 2018 Mar; 194(3):215-224. PubMed ID: 29022050
[TBL] [Abstract][Full Text] [Related]
20. A new subtype of diffuse midline glioma, H3 K27 and BRAF/FGFR1 co-altered: a clinico-radiological and histomolecular characterisation.
Auffret L; Ajlil Y; Tauziède-Espariat A; Kergrohen T; Puiseux C; Riffaud L; Blouin P; Bertozzi AI; Leblond P; Blomgren K; Froelich S; Picca A; Touat M; Sanson M; Beccaria K; Blauwblomme T; Dangouloff-Ros V; Boddaert N; Varlet P; Debily MA; Grill J; Castel D
Acta Neuropathol; 2023 Dec; 147(1):2. PubMed ID: 38066305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
